In this episode of Psychedelics Weekly, Kyle is joined by another new voice from the PT team: one of the main instructors and facilitators from our Vital program, Diego Pinzon.  While from Colombia, Diego was a research assistant at Melbourne’s Psychae Institute and is one of the researchers in the St. Vincent’s Melbourne trial, Australia’s first trial using psilocybin for end of life depression and anxiety. So while we’re not deeming him our Australia expert (unless you want that title… Diego?), we thought it would be interesting to have an insider review their big announcement: that beginning July 1, approved psychiatrists in Australia will be able to prescribe medicines containing psilocybin and MDMA for treatment-resistant depression and post-traumatic stress disorder, respectively.  They cover the details, unknowns, and concerns: Is there enough time to train enough people? Do they have the infrastructure for this? What are the substances actually going to be? What percentage of people who apply will be granted access? What will it cost? And while psychiatrists will be able to prescribe, how much will the program really focus on therapy?  And they discuss Vancouver’s Filament Health creating the world’s first ayahuasca pill, which is close to FDA authorization to begin a Phase 1 trial. Of course this news begs some questions as well, mainly: with psychedelic use being such an active experience, how much does something like this change our relationship to ayahuasca? And with a consistent, more predictable experience, does that kill the magic? www.psychedelicstoday.com